Form 8-K Panbela Therapeutics, For: May 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
H.C. Wainwright Downgrades Panbella Therapeutics (PBLA) to Neutral
May 16, 2024 11:31 AM EDTH.C. Wainwright analyst Joseph Pantginis downgraded Panbella Therapeutics (NASDAQ: PBLA) from Buy to Neutral.
The analyst comments "Yesterday after the close, Panbela announced 1Q24 results, posting 1Q24 EPS of ($2.28) compared with our estimate of ($1.23) and consensus of ($1.62). The company ended the quarter with $262,000 in cash. Per management, current cash burn... More
